Very high molecular weight β-glucans

Details Very high molecular weight β-glucans Very high molecular weight β-glucans

2006-04-04

2006-04-04

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S123100, C536S123120, C536S124000, C514S885000, C514S944000, C514S951000, C514S959000, C514S962000

Reexamination Certificate

active

07022685

ABSTRACT:
The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble β-glucan composition comprising β-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).

REFERENCES:
patent: 3943247 (1976-03-01), Komatsu et al.
patent: 4138479 (1979-02-01), Truscheit et al.
patent: 4237266 (1980-12-01), Sugiura et al.
patent: 4707471 (1987-11-01), Larm et al.
patent: 4739046 (1988-04-01), Di Luzio et al.
patent: 4761402 (1988-08-01), Williams et al.
patent: 4810646 (1989-03-01), Jamas et al.
patent: 4946450 (1990-08-01), Erwin
patent: 4975421 (1990-12-01), Williams et al.
patent: 4992540 (1991-02-01), Jamas et al.
patent: 5032401 (1991-07-01), Jamas et al.
patent: 5057503 (1991-10-01), Czop et al.
patent: 5320849 (1994-06-01), Hagiwara et al.
patent: 5322841 (1994-06-01), Jamas et al.
patent: 5401647 (1995-03-01), Tanaka et al.
patent: 5474984 (1995-12-01), Tanaka et al.
patent: 5488040 (1996-01-01), Jamas et al.
patent: 5504079 (1996-04-01), Jamas et al.
patent: 5532223 (1996-07-01), Jamas et al.
patent: 5622939 (1997-04-01), Jamas et al.
patent: 5783569 (1998-07-01), Jamas et al.
patent: 5817643 (1998-10-01), Jamas et al.
patent: 6084092 (2000-07-01), Wakshull et al.
patent: 6369216 (2002-04-01), Patchen et al.
patent: 0322393 (1989-01-01), None
patent: 0 322 393 (1989-06-01), None
patent: 0416343 (1991-03-01), None
patent: 0463540 (1992-01-01), None
patent: 2076418 (1981-12-01), None
patent: 55071701 (1980-08-01), None
patent: 56076401 (1981-09-01), None
patent: 59045301 (1984-06-01), None
patent: 59210901 (1995-04-01), None
patent: 91/03248 (1991-03-01), None
patent: 91/03495 (1991-03-01), None
patent: 92/13896 (1992-08-01), None
patent: 94/03498 (1994-02-01), None
patent: 94/03500 (1994-02-01), None
patent: 94/04163 (1994-03-01), None
Janusz, M.J., et al., “Isolation of Soluble Yeast β-Glucans that Inhibit Human Monocyte Phagocytosis Mediated by β-Glucans Receptors,”J. Immunol., 137:3270-3276 (1986).
Manners, D.J., et al., “The Structure of a β-(-3)-D-Glucan from Yeast Cell Walls,”Biochem. J., 135:19-30 (1973).
Fleet, G.H., et al., “Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls ofSaccharomyces cerevisiae,” J. Gen. Microbio., 94:180-192 (1976).
Miyazaki, T., et al., “Structural Examination of Antitumour, Water-Soluble Glucans fromGrifora umbellataby Use of Four Types of Glucanases,”Carbohydrate Research, 65:235-243 (1978).
Reiskind, J.B. and Mullins, J.T., “Molecular Architecture of the Hyphal Wall ofAchlya ambisexualisRaper. II. Ultrastructural Analyses and a Proposed Model,”Can. J. Microbiol., 27:1100-1105 (1981).
Latgé, J.P., et al., “Composition Chimique et Ultrastructure des Parois des Hyphaux et des Azygospores deConidiobolus obscurus,” Can. J. Microbiol., 30:1507-1521 (1984).
Sherwood, E.R., et al., “Soluble Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases,”Chemical Abstracts, 108:179752v (1988).
Hara, C., et al., “A Branched (1-3)-β-D-Glucan from a Water Extract ofDictyophora indusiataFISCH,”Carb. Res., 145:237-246 (1986).
Goldman, R., “Induction of a β-1,3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid or 1,25-dihydroxyvitamin D3,”Immunology, 63:319-324 (1988).
Konopski, A., et al., “Phagocytosis of β-1,3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors,”Scand. J. Immunol., 33:297-306 (1991).
Williams, D.L., et al., “Development of a Water-Soluble, Sulfated (1-3)-β-D-Glucan Biological Response Modifier Derived fromSaccharomyces cerevisiae,” Carbohydrate Research, 235:247-257 (1992).
Williams, D.L., et al., “A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators,”Develop. Biol. Standard, 77:129-136 (1992).
Williams, D.L., et al., Development, Physiochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived fromSaccharomyces cerevisiae, Immunopharmacology, 22:139-156 (1991).
Pretus, H.A., et al., “Isolation, Physiochemical Characterization and Preclinical Efficacy Evaluation of Soluble Scleroglucan,”J. Pharmacol. Exp. Therap., 257:500-510 (1991).
Bacon, J., et al., “The Glucan Components of the Cell Wall of Baker's Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure,”Biochem. J., 114:557-567 (1969).
Vestnick Federalniho Uradu Pro Vynalezy, 10:111 (1989).
Vestnick Federalniho Uradu Pro Vynalezy, 11:122-123 (1989).
Onderdonk, A.B., et al., “Anti-Infective Effect of Poly-β1-6-Glucotrisyl-β1-3-Glucopyranose Glucan In Vivo,”Infect. Immun., 60:1642-1647 (1992).
Abel, G. and Czop, J.K., “Activation of Human Monocyte GM-CSF and TNF-α Production by Particulate Yeast Glucan,” International Congress for Infectious Diseases, Montreal Canada (Abstract) Jul. 15-19, 1990.
Chihara, G., et al., “Lentinan as a Host Defense Potentiator (HPD),”Int. J. Immunotherapy, 4:145-154 (1989).
Sherwood, E.R., et al., “Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan,”Int. J. Immunopharm., 9(3):261-267 (1987).
Williams, D.L., et al., “Pre-clinical Safety Evaluation of Soluble Glucan,”Int. J. Immunopharm., 10(4):405-414 (1988).
Browder, W., et al., “Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient,”Ann. Surg., p. 605-613 (1990).
Jamas, et al., “A Novel Class of Macrophage-Activating Immunomodulators,” ACS Symposium Series,Polymeric Drugs and Delivery Systems, Chapter 5, pp. 44-51 (1991).
Shiota, M., et al., “Comparison of β-Glucan Structures in a Cell Wall Mutant ofSaccharomyces cerevisiaeand the Wild Type,”J. Biochem.98:1301-1307 (1985).
Jamas, et al., “PGG-A Novel Class of Macrophage Activating Immunomodulators,” International Congress for Infectious Diseases, Montreal, Canada (Abstract), Jul. 15-19, 1990.
Katzen, et al., “PGG, a Glucose Polymer, Primes Interleukin-1 and Tumor Necrosis Factor Production,” International Congress for Infectious Diseases, Montreal, Canada (Abstract), Jul. 15-19, 1990.
Shah, et al., “Influence of PGG on the Phagocytosis ofStaphylococcus aureusorEscherichia coli,” International Congress for Infectious Diseases, Montreal, Canada (Abstract), Jul. 15-19, 1990.
Onderdonk, A.B., “Effect of a New Carbohydrate Polymer on Survival in a Mouse Model for ExperimentalE. coliSepsis,” International Congress for Infectious Diseases, Montreal, Canada (Abstract), Jul. 15-19, 1990.
Arbo, A. and Santos, J.I., “Effect of PGG on Neutrophil (PMN) Function in Experimental Malnutrition,” International Congress for Infectious Diseases, Montreal, Canada (Abstract), Jul. 15-19, 1990.
Onderdonk, A.B., et al., “Protective Effect of a New Carbohydrate Polymer in a Rat Model for Experimental Intraabdominal Sepsis,” First International Congress on Biological Response Modifiers, Quebec, Canada, (Abstract), Mar., 1991.
Lagrange, P.H. and Fourgeaud, M., “Enhanced Natural Resistance Against Severe DisseminatedCandida albicans,” Int'l J. Experimental Clin. Chemotherapy, 40(1):48-55 (1991).
Sakurai, et al., “Intravenously Administered (1-3)-β-D-Glucan, SSG, Obtained fromSclerotinia sclerotiorumIFO9395 Augments Murine Peritneal Macrophage Function In Vivo,”Chem. Pharm. Bull., 40(8):2120-2124 (1992).
Jamas, et al., “PGG-A Novel Class of Macrophage Activating Immunomodulators,”Polymer Preprints, 31:194-195 (1990).
Sasaki, et al., “Antitumor Activity of Degraded Products of Lentinan: Its C

Affiliated with

Also associated with

Rating

Very high molecular weight β-glucans does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Very high molecular weight β-glucans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Very high molecular weight β-glucans will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3573658